Cell Therapeutics, Inc. (CTI) Reduces Net Loss for Third Quarter and Nine ... Sacramento Bee The European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who ... |
